Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery

Open access
Han, Ri, Yoon, Hongryul, Kim, Gahee, Lee, Hyundo, Lee, Yoonji·2023·Pharmaceuticals

Abstract

Artificial intelligence (AI) has permeated various sectors, including the pharmaceutical industry and research, where it has been utilized to efficiently identify new chemical entities with desirable properties. The application of AI algorithms to drug discovery presents both remarkable opportunities and challenges. This review article focuses on the transformative role of AI in medicinal chemistry. We delve into the applications of machine learning and deep learning techniques in drug screening and design, discussing their potential to expedite the early drug discovery process. In particular, we provide a comprehensive overview of the use of AI algorithms in predicting protein structures, drug–target interactions, and molecular properties such as drug toxicity. While AI has accelerated the drug discovery process, data quality issues and technological constraints remain challenges. Nonetheless, new relationships and methods have been unveiled, demonstrating AI’s expanding potential in predicting and understanding drug interactions and properties. For its full potential to be realized, interdisciplinary collaboration is essential. This review underscores AI’s growing influence on the future trajectory of medicinal chemistry and stresses the importance of ongoing synergies between computational and domain experts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph16091259

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 205

  1. Chen, 2023, Artificial intelligence for drug discovery: Resources, methods, and applications, Mol. Ther. Nucl. Acids, 31, 691, 10.1016/j.omtn.2023.02.019 · DOI · Paper page
  2. Cifci, M.A. (2023). A Deep Learning-Based Framework for Uncertainty Quantification in Medical Imaging Using the DropWeak Technique: An Empirical Study with Baresnet. Diagnostics, 13. · DOI
  3. Wong, 2023, Deep Learning of Sparse Patterns in Medical IoT for Efficient Big Data Harnessing, IEEE Access, 11, 25856, 10.1109/ACCESS.2023.3256721 · DOI
  4. Alya, 2021, Artificial intelligence in drug design: Algorithms, applications, challenges and ethics, Future Drug Discov., 3, FDD59, 10.4155/fdd-2020-0028 · DOI
  5. Zhu, 2020, Big Data and Artificial Intelligence Modeling for Drug Discovery, Annu. Rev. Pharmacol., 60, 573, 10.1146/annurev-pharmtox-010919-023324 · DOI · Paper page
  6. Hu, 2019, Application of Machine Learning Approaches for the Design and Study of Anticancer Drugs, Curr. Drug Targets, 20, 488, 10.2174/1389450119666180809122244 · DOI
  7. Tong, 2021, Generative Models for De Novo Drug Design, J. Med. Chem., 64, 14011, 10.1021/acs.jmedchem.1c00927 · DOI · Paper page
  8. Cheng, 2021, Molecular design in drug discovery: A comprehensive review of deep generative models, Brief Bioinform., 22, bbab344, 10.1093/bib/bbab344 · DOI · Paper page
  9. Xue, 2019, Advances and challenges in deep generative models for de novo molecule generation, Wires Comput. Mol. Sci., 9, e1395, 10.1002/wcms.1395 · DOI
  10. Vemula, 2023, CADD, AI and ML in drug discovery: A comprehensive review, Eur. J. Pharm. Sci., 181, 106324, 10.1016/j.ejps.2022.106324 · DOI · Paper page
  11. Cerchia, 2023, New avenues in artificial-intelligence-assisted drug discovery, Drug Discov. Today, 28, 103516, 10.1016/j.drudis.2023.103516 · DOI
  12. Dara, 2022, Machine Learning in Drug Discovery: A Review, Artif. Intell. Rev., 55, 1947, 10.1007/s10462-021-10058-4 · DOI · Paper page
  13. Priya, 2022, Machine learning approaches and their applications in drug discovery and design, Chem. Biol. Drug Des., 100, 136, 10.1111/cbdd.14057 · DOI
  14. Guedes, 2021, New machine learning and physics-based scoring functions for drug discovery, Sci. Rep., 11, 3198, 10.1038/s41598-021-82410-1 · DOI · Paper page
  15. Tamura, 2023, Large-scale prediction of activity cliffs using machine and deep learning methods of increasing complexity, J. Cheminform., 15, 4, 10.1186/s13321-022-00676-7 · DOI
  16. Stumpfe, 2020, Advances in exploring activity cliffs, J. Comput. Aid. Mol. Des., 34, 929, 10.1007/s10822-020-00315-z · DOI
  17. Heikamp, 2012, Prediction of Activity Cliffs Using Support Vector Machines, J. Chem. Inf. Model, 52, 2354, 10.1021/ci300306a · DOI
  18. Bajorath, 2022, Evolution of Support Vector Machine and Regression Modeling in Chemoinformatics and Drug Discovery, J. Comput. Aid. Mol. Des., 36, 355, 10.1007/s10822-022-00442-9 · DOI · Paper page
  19. Warszycki, 2021, Pharmacoprint: A Combination of a Pharmacophore Fingerprint and Artificial Intelligence as a Tool for Computer-Aided Drug Design, J. Chem. Inf. Model, 61, 5054, 10.1021/acs.jcim.1c00589 · DOI
  20. Jayaraj, 2019, Ligand based virtual screening using SVM on GPU, Comput. Biol. Chem., 83, 107143, 10.1016/j.compbiolchem.2019.107143 · DOI
  21. Ogura, 2019, Support Vector Machine model for hERG inhibitory activities based on the integrated hERG database using descriptor selection by NSGA-II, Sci. Rep., 9, 12220, 10.1038/s41598-019-47536-3 · DOI
  22. Vogt, 2017, Support Vector Machine Classification and Regression Prioritize Different Structural Features for Binary Compound Activity and Potency Value Prediction, ACS Omega, 2, 6371, 10.1021/acsomega.7b01079 · DOI
  23. 2021, Epigenetic Target Profiler: A Web Server to Predict Epigenetic Targets of Small Molecules, J. Chem. Inf. Model, 61, 1550, 10.1021/acs.jcim.1c00045 · DOI
  24. Tong, 2019, Identifying potential drug targets in hepatocellular carcinoma based on network analysis and one-class support vector machine, Sci. Rep., 9, 10442, 10.1038/s41598-019-46540-x · DOI
  25. Kwon, S., Bae, H., Jo, J., and Yoon, S. (2019). Comprehensive ensemble in QSAR prediction for drug discovery. BMC Bioinform., 20. · DOI · Paper page
  26. Kaiser, 2018, A Machine Learning Approach for Predicting HIV Reverse Transcriptase Mutation Susceptibility of Biologically Active Compounds, J. Chem. Inf. Model, 58, 1544, 10.1021/acs.jcim.7b00475 · DOI
  27. Hu, J., Zhou, L.W., Li, B., Zhang, X.L., and Chen, N.S. (2021). Improve hot region prediction by analyzing different machine learning algorithms. BMC Bioinform., 22. · DOI
  28. Celebi, R., Uyar, H., Yasar, E., Gumus, O., Dikenelli, O., and Dumontier, M. (2019). Evaluation of knowledge graph embedding approaches for drug-drug interaction prediction in realistic settings. BMC Bioinform., 20. · DOI
  29. Cai, 2019, Deep Learning-Based Prediction of Drug-Induced Cardiotoxicity, J. Chem. Inf. Model, 59, 1073, 10.1021/acs.jcim.8b00769 · DOI · Paper page
  30. Madhukar, 2019, A Bayesian machine learning approach for drug target identification using diverse data types, Nat. Commun., 10, 5221, 10.1038/s41467-019-12928-6 · DOI · Paper page
  31. Saha, S., Chatterjee, P., Halder, A.K., Nasipuri, M., Basu, S., and Plewczynski, D. (2022). ML-DTD: Machine Learning-Based Drug Target Discovery for the Potential Treatment of COVID-19. Vaccines, 10. · DOI
  32. Khan, A.K.A., and Malim, N.H.A.H. (2023). Comparative Studies on Resampling Techniques in Machine Learning and Deep Learning Models for Drug-Target Interaction Prediction. Molecules, 28. · DOI
  33. Carpenter, 2018, Machine Learning-based Virtual Screening and Its Applications to Alzheimer’s Drug Discovery: A Review, Curr. Pharm. Des., 24, 3347, 10.2174/1381612824666180607124038 · DOI · Paper page
  34. Zakharov, 2016, QSAR Modeling and Prediction of Drug-Drug Interactions, Mol. Pharm., 13, 545, 10.1021/acs.molpharmaceut.5b00762 · DOI
  35. Cooper, 2021, Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning, ACS Omega, 6, 4857, 10.1021/acsomega.0c05303 · DOI
  36. Brekkan, 2019, Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM, J. Pharmacokinet. Pharmacodyn., 46, 591, 10.1007/s10928-019-09658-z · DOI
  37. Tamposis, 2019, Semi-supervised learning of Hidden Markov Models for biological sequence analysis, Bioinformatics, 35, 2208, 10.1093/bioinformatics/bty910 · DOI
  38. Nguyen, N.P., Nute, M., Mirarab, S., and Warnow, T. (2016). HIPPI: Highly accurate protein family classification with ensembles of HMMs. BMC Genom., 17. · DOI
  39. Li, J.F., Lee, J.Y., and Liao, L. (2021). A new algorithm to train hidden Markov models for biological sequences with partial labels. BMC Bioinform., 22. · doi:10.1186/s12859-021-04080-0
  40. Tamposis, 2019, JUCHMME: A Java Utility for Class Hidden Markov Models and Extensions for biological sequence analysis, Bioinformatics, 35, 5309, 10.1093/bioinformatics/btz533 · doi:10.1093/bioinformatics/btz533
  41. Kaur, 2023, Mapping the FtsQBL divisome components in bacterial NTD pathogens as potential drug targets, Front. Genet., 13, 1010870, 10.3389/fgene.2022.1010870 · DOI
  42. Gupta, 2021, Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening, J. Chem. Inf. Model, 61, 4236, 10.1021/acs.jcim.1c00710 · DOI
  43. Madugula, 2021, Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing, Comput. Biol. Med., 138, 104856, 10.1016/j.compbiomed.2021.104856 · DOI
  44. Huang, 2021, Drug-drug similarity measure and its applications, Brief Bioinform., 22, bbaa265
  45. Nedyalkova, M., and Simeonov, V. (2021). Partitioning Pattern of Natural Products Based on Molecular Properties Descriptors Representing Drug-Likeness. Symmetry, 13. · doi:10.3390/sym13040546
  46. McKay, 2022, Essential Dynamics Ensemble Docking for Structure-Based GPCR Drug Discovery, Front. Mol. Biosci., 9, 879212, 10.3389/fmolb.2022.879212 · DOI
  47. Chandak, 2020, Using machine learning to improve ensemble docking for drug discovery, Proteins, 88, 1263, 10.1002/prot.25899 · DOI
  48. Yang, 2022, Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy, Comput. Struct. Biotechnol. J., 20, 2442, 10.1016/j.csbj.2022.05.023 · DOI
  49. Andronov, 2021, Exploring Chemical Reaction Space with Reaction Difference Fingerprints and Parametric t-SNE, ACS Omega, 6, 30743, 10.1021/acsomega.1c04778 · DOI
  50. Barnard, 2020, Less may be more: An informed reflection on molecular descriptors for drug design and discovery, Mol. Syst. Des. Eng., 5, 317, 10.1039/C9ME00109C · DOI
  51. Liu, 2021, GraphDTI: A robust deep learning predictor of drug-target interactions from multiple heterogeneous data, J. Cheminform., 13, 58, 10.1186/s13321-021-00540-0 · DOI
  52. Xu, 2020, A t-SNE Based Classification Approach to Compositional Microbiome Data, Front. Genet., 11, 620143, 10.3389/fgene.2020.620143 · DOI
  53. Karagiannaki, I., Gourlia, K., Lagani, V., Pantazis, Y., and Tsamardinos, I. (2022). Learning biologically-interpretable latent representations for gene expression data. Mach. Learn., 1–31. · DOI
  54. Zhang, L.P., Tang, L., Zhang, S.L., Wang, Z.Z., Shen, X.H., and Zhang, Z.Q. (2021). A Self-Adaptive Reinforcement-Exploration Q-Learning Algorithm. Symmetry, 13. · doi:10.3390/sym13061057
  55. Tang, B.W., He, F.M., Liu, D.P., He, F., Wu, T., Fang, M.J., Niu, Z.M., Wu, Z., and Xu, D. (2022). AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2. Biomolecules, 12. · DOI
  56. Wang, 2020, Towards efficient discovery of green synthetic pathways with Monte Carlo tree search and reinforcement learning, Chem. Sci., 11, 10959, 10.1039/D0SC04184J · DOI
  57. Lee, G., Jang, G.H., Kang, H.Y., and Song, G. (2021). Predicting aptamer sequences that interact with target proteins using an aptamer-protein interaction classifier and a Monte Carlo tree search approach. PLoS ONE, 16. · DOI
  58. Yoshizawa, 2022, Selective Inhibitor Design for Kinase Homologs Using Multiobjective Monte Carlo Tree Search, J. Chem. Inf. Model, 62, 5351, 10.1021/acs.jcim.2c00787 · DOI
  59. Li, 2021, Structure-based de novo drug design using 3D deep generative models, Chem. Sci., 12, 13664, 10.1039/D1SC04444C · DOI · Paper page
  60. Genheden, 2020, AiZynthFinder: A fast, robust and flexible open-source software for retrosynthetic planning, J. Cheminform., 12, 70, 10.1186/s13321-020-00472-1 · DOI · Paper page
  61. Skalic, 2019, PlayMolecule BindScope: Large scale CNN-based virtual screening on the web, Bioinformatics, 35, 1237, 10.1093/bioinformatics/bty758 · DOI
  62. Haneczok, 2021, Machine learning enabled identification of potential SARS-CoV-2 3CLpro inhibitors based on fixed molecular fingerprints and Graph-CNN neural representations, J. Biomed. Inform., 119, 103821, 10.1016/j.jbi.2021.103821 · DOI
  63. Huo, 2023, An improved 3D quantitative structure-activity relationships (QSAR) of molecules with CNN-based partial least squares model, Artif. Intell. Life Sci., 3, 100065
  64. Qian, 2022, CAT-CPI: Combining CNN and transformer to learn compound image features for predicting compound-protein interactions, Front. Mol. Biosci., 9, 963912, 10.3389/fmolb.2022.963912 · DOI
  65. Jiang, 2019, FRSite: Protein drug binding site prediction based on faster R-CNN, J. Mol. Graph. Model., 93, 107454, 10.1016/j.jmgm.2019.107454 · DOI
  66. Hirohara, M., Saito, Y., Koda, Y., Sato, K., and Sakakibara, Y. (2018). Convolutional neural network based on SMILES representation of compounds for detecting chemical motif. BMC Bioinform., 19. · DOI · Paper page
  67. Hu, 2023, De novo drug design based on Stack-RNN with multi-objective reward-weighted sum and reinforcement learning, J. Mol. Model., 29, 121, 10.1007/s00894-023-05523-6 · DOI
  68. Chen, 2022, Recurrent neural network (RNN) model accelerates the development of antibacterial metronidazole derivatives, RSC Adv., 12, 22893, 10.1039/D2RA01807A · doi:10.1039/d2ra01807a
  69. Lim, 2019, Predicting Drug-Target Interaction Using a Novel Graph Neural Network with 3D Structure-Embedded Graph Representation, J. Chem. Inf. Model., 59, 3981, 10.1021/acs.jcim.9b00387 · DOI · Paper page
  70. Plisson, 2022, Natural product drug discovery in the artificial intelligence era, Chem. Sci., 13, 1526, 10.1039/D1SC04471K · DOI · Paper page
  71. Yang, 2017, Deep belief network-based drug identification using near infrared spectroscopy, J. Innov. Opt. Health Sci., 10, 1630011, 10.1142/S1793545816300111 · doi:10.1142/s1793545816300111
  72. Griffiths, 2020, Constrained Bayesian optimization for automatic chemical design using variational autoencoders, Chem. Sci., 11, 577, 10.1039/C9SC04026A · DOI · Paper page
  73. Sajadi, S.Z., Chahooki, M.A.Z., Gharaghani, S., and Abbasi, K. (2021). AutoDTI plus plus: Deep unsupervised learning for DTI prediction by autoencoders. BMC Bioinform., 22. · DOI
  74. Zhang, 2022, Drug-protein interaction prediction via variational autoencoders and attention mechanisms, Front. Genet., 13, 1032779, 10.3389/fgene.2022.1032779 · DOI
  75. Song, 2023, DNMG: Deep molecular generative model by fusion of 3D information for de novo drug design, Methods, 211, 10, 10.1016/j.ymeth.2023.02.001 · DOI
  76. Hussain, 2020, High-content image generation for drug discovery using generative adversarial networks, Neural Netw., 132, 353, 10.1016/j.neunet.2020.09.007 · DOI
  77. Yu, 2023, DGANDDI: Double Generative Adversarial Networks for Drug-Drug Interaction Prediction, IEEE/ACM Trans. Comput. Biol. Bioinform., 20, 1854, 10.1109/TCBB.2022.3219883 · DOI
  78. Zhao, 2020, GANsDTA: Predicting Drug-Target Binding Affinity Using GANs, Front. Genet., 10, 1243, 10.3389/fgene.2019.01243 · DOI
  79. Hicks, 2022, On evaluation metrics for medical applications of artificial intelligence, Sci. Rep., 12, 5979, 10.1038/s41598-022-09954-8 · DOI · Paper page
  80. Mendez, 2019, ChEMBL: Towards direct deposition of bioassay data, Nucleic Acids Res., 47, D930, 10.1093/nar/gky1075 · DOI · Paper page
  81. Irwin, 2020, ZINC20-A Free Ultralarge-Scale Chemical Database for Ligand Discovery, J. Chem. Inf. Model., 60, 6065, 10.1021/acs.jcim.0c00675 · DOI · Paper page
  82. Pence, 2010, ChemSpider: An Online Chemical Information Resource, J. Chem. Educ., 87, 1123, 10.1021/ed100697w · DOI · Paper page
  83. Avram, 2022, DrugCentral 2023 extends human clinical data and integrates veterinary drugs, Nucleic Acids Res., 51, D1276, 10.1093/nar/gkac1085 · DOI · Paper page
  84. Kanehisa, 2000, KEGG: Kyoto Encyclopedia of Genes and Genomes, Nucleic Acids Res., 28, 27, 10.1093/nar/28.1.27 · DOI · Paper page
  85. Karp, 2019, The BioCyc collection of microbial genomes and metabolic pathways, Brief Bioinform., 20, 1085, 10.1093/bib/bbx085 · DOI · Paper page
  86. Gillespie, 2022, The reactome pathway knowledgebase 2022, Nucleic Acids Res., 50, D687, 10.1093/nar/gkab1028 · DOI · Paper page
  87. Wishart, 2022, HMDB 5.0: The Human Metabolome Database for 2022, Nucleic Acids Res., 50, D622, 10.1093/nar/gkab1062 · DOI · Paper page
  88. Orchard, 2014, The MIntAct project-IntAct as a common curation platform for 11 molecular interaction databases, Nucleic Acids Res., 42, D358, 10.1093/nar/gkt1115 · DOI · Paper page
  89. Szklarczyk, 2016, STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data, Nucleic Acids Res., 44, D380, 10.1093/nar/gkv1277 · DOI · Paper page
  90. Gilson, 2016, BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology, Nucleic Acids Res., 44, D1045, 10.1093/nar/gkv1072 · DOI · Paper page
  91. Zhou, 2022, Therapeutic target database update 2022: Facilitating drug discovery with enriched comparative data of targeted agents, Nucleic Acids Res., 50, D1398, 10.1093/nar/gkab953 · DOI · Paper page
  92. Harding, 2022, The IUPHAR/BPS guide to PHARMACOLOGY in 2022: Curating pharmacology for COVID-19, malaria and antibacterials, Nucleic Acids Res., 50, D1282, 10.1093/nar/gkab1010 · DOI · Paper page
  93. Freshour, 2021, Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts, Nucleic Acids Res., 49, D1144, 10.1093/nar/gkaa1084 · DOI · Paper page
  94. Davis, 2022, Comparative Toxicogenomics Database (CTD): Update 2023, Nucleic Acids Res., 51, D1257, 10.1093/nar/gkac833 · DOI · Paper page
  95. Ganter, 2006, Toxicogenomics in drug discovery and development: Mechanistic analysis of compound/class-dependent effects using the DrugMatrix® database, Pharmacogenomics, 7, 1025, 10.2217/14622416.7.7.1025 · DOI
  96. Kuhn, 2016, The SIDER database of drugs and side effects, Nucleic Acids Res., 44, D1075, 10.1093/nar/gkv1075 · DOI · Paper page
  97. Blum, 2022, InterPro in 2022, Nucleic Acids Res., 51, D418
  98. Benson, 2012, GenBank, Nucleic Acids Res., 41, D36, 10.1093/nar/gks1195 · DOI · Paper page
  99. Burley, 2022, RCSB Protein Data Bank (RCSB.org): Delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence/machine learning, Nucleic Acids Res., 51, D488, 10.1093/nar/gkac1077 · DOI · Paper page
  100. Feng, 2004, Ligand Depot: A data warehouse for ligands bound to macromolecules, Bioinformatics, 20, 2153, 10.1093/bioinformatics/bth214 · DOI · Paper page
  101. Sorokina, 2021, COCONUT online: Collection of Open Natural Products database, J. Cheminform., 13, 2, 10.1186/s13321-020-00478-9 · DOI · Paper page
  102. Landaburu, 2020, TDR Targets 6: Driving drug discovery for human pathogens through intensive chemogenomic data integration, Nucleic Acids Res., 48, D992
  103. Bryant, 2023, Deep learning for protein complex structure prediction, Curr. Opin. Struct. Biol., 79, 102529, 10.1016/j.sbi.2023.102529 · DOI
  104. Ivankov, D.N., and Finkelstein, A.V. (2020). Solution of Levinthal’s Paradox and a Physical Theory of Protein Folding Times. Biomolecules, 10. · DOI
  105. Rose, 2021, Protein folding—Seeing is deceiving, Protein Sci., 30, 1606, 10.1002/pro.4096 · DOI
  106. Sorokina, I., Mushegian, A.R., and Koonin, E.V. (2022). Is Protein Folding a Thermodynamically Unfavorable, Active, Energy-Dependent Process?. Int. J. Mol. Sci., 23. · DOI
  107. Muhammed, 2019, Homology modeling in drug discovery: Overview, current applications, and future perspectives, Chem. Biol. Drug Des., 93, 12, 10.1111/cbdd.13388 · DOI · Paper page
  108. Burley, S.K., Berman, H.M., Duarte, J.M., Feng, Z.K., Flatt, J.W., Hudson, B.P., Lowe, R., Peisach, E., Piehl, D.W., and Rose, Y. (2022). Protein Data Bank: A Comprehensive Review of 3D Structure Holdings and Worldwide Utilization by Researchers, Educators, and Students. Biomolecules, 12. · DOI
  109. Burley, 2022, RCSB Protein Data Bank: Celebrating 50 years of the PDB with new tools for understanding and visualizing biological macromolecules in 3D, Protein Sci., 31, 187, 10.1002/pro.4213 · DOI · Paper page
  110. Sali, 1993, Comparative Protein Modeling by Satisfaction of Spatial Restraints, J. Mol. Biol., 234, 779, 10.1006/jmbi.1993.1626 · DOI · Paper page
  111. Webb, 2021, Protein Structure Modeling with MODELLER, Methods Mol. Biol., 2199, 239, 10.1007/978-1-0716-0892-0_14 · DOI · Paper page
  112. Studer, G., Tauriello, G., Bienert, S., Biasini, M., Johner, N., and Schwede, T. (2021). ProMod3—A versatile homology modelling toolbox. PLoS Comput. Biol., 17. · DOI · Paper page
  113. Studer, 2020, QMEANDisCo-distance constraints applied on model quality estimation, Bioinformatics, 36, 1765, 10.1093/bioinformatics/btz828 · DOI · Paper page
  114. Waterhouse, 2018, SWISS-MODEL: Homology modelling of protein structures and complexes, Nucleic Acids Res., 46, W296, 10.1093/nar/gky427 · DOI · Paper page
  115. Roy, 2010, I-TASSER: A unified platform for automated protein structure and function prediction, Nat. Protoc., 5, 725, 10.1038/nprot.2010.5 · DOI · Paper page
  116. Kryshtafovych, 2018, Evaluation of the template-based modeling in CASP12, Proteins, 86, 321, 10.1002/prot.25425 · DOI
  117. Zheng, 2021, Protein structure prediction using deep learning distance and hydrogen-bonding restraints in CASP14, Proteins, 89, 1734, 10.1002/prot.26193 · DOI
  118. Jumper, 2021, Applying and improving AlphaFold at CASP14, Proteins, 89, 1711, 10.1002/prot.26257 · DOI · Paper page
  119. Senior, 2020, Improved protein structure prediction using potentials from deep learning, Nature, 577, 706, 10.1038/s41586-019-1923-7 · DOI · Paper page
  120. Anishchenko, 2021, Protein tertiary structure prediction and refinement using deep learning and Rosetta in CASP14, Proteins, 89, 1722, 10.1002/prot.26194 · DOI
  121. Tourlet, 2023, AlphaFold2 Update and Perspectives, BioMedInformatics, 3, 378, 10.3390/biomedinformatics3020025 · DOI
  122. Sciacca, 2020, Lipid-Chaperone Hypothesis: A Common Molecular Mechanism of Membrane Disruption by Intrinsically Disordered Proteins, ACS Chem. Neurosci., 11, 4336, 10.1021/acschemneuro.0c00588 · DOI
  123. Fantini, 2003, How sphingolipids bind and shape proteins: Molecular basis of lipid-protein interactions in lipid shells, rafts and related biomembrane domains, Cell. Mol. Life Sci., 60, 1027, 10.1007/s00018-003-3003-1 · DOI
  124. Lee, 2022, Comparative studies of AlphaFold, RoseTTAFold and Modeller: A case study involving the use of G-protein-coupled receptors, Brief Bioinform., 23, bbac308, 10.1093/bib/bbac308 · DOI
  125. Tovar, 2007, Comparison of 2D fingerprint methods for multiple-template similarity searching on compound activity classes of increasing structural diversity, ChemMedChem, 2, 208, 10.1002/cmdc.200600225 · DOI
  126. Cedron, 2021, A review on machine learning approaches and trends in drug discovery, Comput. Struct. Biotech. J., 19, 4538, 10.1016/j.csbj.2021.08.011 · DOI · Paper page
  127. Ding, 2021, Molecular fingerprint-based machine learning assisted QSAR model development for prediction of ionic liquid properties, J. Mol. Liq., 326, 115212, 10.1016/j.molliq.2020.115212 · DOI
  128. Riniker, 2013, Open-source platform to benchmark fingerprints for ligand-based virtual screening, J. Cheminform., 5, 26, 10.1186/1758-2946-5-26 · DOI · Paper page
  129. Ojeda, 2015, Molecular fingerprint similarity search in virtual screening, Methods, 71, 58, 10.1016/j.ymeth.2014.08.005 · DOI · Paper page
  130. Gao, 2020, Are 2D fingerprints still valuable for drug discovery?, Phys. Chem. Chem. Phys., 22, 8373, 10.1039/D0CP00305K · DOI
  131. Rogers, 2010, Extended-Connectivity Fingerprints, J. Chem. Inf. Model., 50, 742, 10.1021/ci100050t · DOI · Paper page
  132. McGregor, 1999, Pharmacophore fingerprinting. 1. Application to QSAR and focused library design, J. Chem. Inf. Comput. Sci., 39, 569, 10.1021/ci980159j · DOI · Paper page
  133. Schwartz, 2013, SMIfp (SMILES fingerprint) Chemical Space for Virtual Screening and Visualization of Large Databases of Organic Molecules, J. Chem. Inf. Model., 53, 1979, 10.1021/ci400206h · DOI
  134. Awale, 2015, Stereoselective virtual screening of the ZINC database using atom pair 3D-fingerprints, J. Cheminform., 7, 3, 10.1186/s13321-014-0051-5 · DOI
  135. Da, 2014, Structural Protein-Ligand Interaction Fingerprints (SPLIF) for Structure-Based Virtual Screening: Method and Benchmark Study, J. Chem. Inf. Model., 54, 2555, 10.1021/ci500319f · DOI · Paper page
  136. Durant, 2002, Reoptimization of MDL keys for use in drug discovery, J. Chem. Inf. Comput. Sci., 42, 1273, 10.1021/ci010132r · DOI · Paper page
  137. (2023, July 22). PubChem Substructure Fingerprint, Available online: https://ftp.ncbi.nlm.nih.gov/pubchem/specifications/pubchem_fingerprints.pdf.
  138. Carhart, 1985, Atom Pairs as Molecular-Features in Structure Activity Studies—Definition and Applications, J. Chem. Inf. Comput. Sci., 25, 64, 10.1021/ci00046a002 · DOI · Paper page
  139. Bender, 2004, Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): Evaluation of performance, J. Chem. Inf. Comput. Sci., 44, 1708, 10.1021/ci0498719 · DOI · Paper page
  140. Schneider, 2016, De Novo Design at the Edge of Chaos, J. Med. Chem., 59, 4077, 10.1021/acs.jmedchem.5b01849 · DOI · Paper page
  141. Mouchlis, V.D., Afantitis, A., Serra, A., Fratello, M., Papadiamantis, A.G., Aidinis, V., Lynch, I., Greco, D., and Melagraki, G. (2021). Advances in De Novo Drug Design: From Conventional to Machine Learning Methods. Int. J. Mol. Sci., 22. · DOI · Paper page
  142. Girin, 2021, Dynamical Variational Autoencoders: A Comprehensive Review, Found. Trends Mach. Learn., 15, 1, 10.1561/2200000089 · DOI · Paper page
  143. Prykhodko, 2019, A de novo molecular generation method using latent vector based generative adversarial network, J. Cheminform., 11, 74, 10.1186/s13321-019-0397-9 · DOI · Paper page
  144. Sachdev, 2019, A comprehensive review of feature based methods for drug target interaction prediction, J. Biomed. Inform., 93, 103159, 10.1016/j.jbi.2019.103159 · DOI · Paper page
  145. Dhakal, 2022, Artificial intelligence in the prediction of protein-ligand interactions: Recent advances and future directions, Brief Bioinform., 23, bbab476, 10.1093/bib/bbab476 · DOI · Paper page
  146. Bissantz, 2010, A Medicinal Chemist’s Guide to Molecular Interactions, J. Med. Chem., 53, 6241, 10.1021/jm100950p · doi:10.1021/jm100950p
  147. Chen, 2016, Regulation of protein-ligand binding affinity by hydrogen bond pairing, Sci. Adv., 2, e1501240, 10.1126/sciadv.1501240 · DOI · Paper page
  148. Anusuya, 2018, Drug-Target Interactions: Prediction Methods and Applications, Curr. Protein Pept. Sci., 19, 537, 10.2174/1389203718666161108091609 · DOI
  149. Bagherian, 2021, Machine learning approaches and databases for prediction of drug-target interaction: A survey paper, Brief Bioinform., 22, 247, 10.1093/bib/bbz157 · DOI · Paper page
  150. Xu, 2021, Application of Machine Learning for Drug-Target Interaction Prediction, Front. Genet., 12, 680117, 10.3389/fgene.2021.680117 · DOI
  151. Yamanishi, 2008, Prediction of drug-target interaction networks from the integration of chemical and genomic spaces, Bioinformatics, 24, I232, 10.1093/bioinformatics/btn162 · DOI · Paper page
  152. Liu, 2015, Improving compound-protein interaction prediction by building up highly credible negative samples, Bioinformatics, 31, 221, 10.1093/bioinformatics/btv256 · DOI · Paper page
  153. Wang, 2021, GanDTI: A multi-task neural network for drug-target interaction prediction, Comput. Biol. Chem., 92, 107476, 10.1016/j.compbiolchem.2021.107476 · DOI
  154. Hecker, 2012, SuperTarget goes quantitative: Update on drug-target interactions, Nucleic Acids Res., 40, D1113, 10.1093/nar/gkr912 · DOI · Paper page
  155. Ding, 2022, Identification of drug-target interactions via multiple kernel-based triple collaborative matrix factorization, Brief Bioinform., 23, bbab582, 10.1093/bib/bbab582 · DOI
  156. Song, 2022, DeepFusion: A deep learning based multi-scale feature fusion method for predicting drug-target interactions, Methods, 204, 269, 10.1016/j.ymeth.2022.02.007 · DOI
  157. Yousefi, 2022, AttentionSiteDTI: An interpretable graph-based model for drug-target interaction prediction using NLP sentence-level relation classification, Brief Bioinform., 23, bbac272, 10.1093/bib/bbac272 · DOI
  158. Li, 2022, Effective drug-target interaction prediction with mutual interaction neural network, Bioinformatics, 38, 3582, 10.1093/bioinformatics/btac377 · DOI
  159. Xia, 2023, MDTips: A multimodal-data-based drug-target interaction prediction system fusing knowledge, gene expression profile, and structural data, Bioinformatics, 39, btad411, 10.1093/bioinformatics/btad411 · DOI
  160. Richard, 2016, ToxCast Chemical Landscape: Paving the Road to 21st Century Toxicology, Chem. Res. Toxicol., 29, 1225, 10.1021/acs.chemrestox.6b00135 · DOI · Paper page
  161. Dix, 2007, The ToxCast program for prioritizing toxicity testing of environmental chemicals, Toxicol. Sci., 95, 5, 10.1093/toxsci/kfl103 · DOI · Paper page
  162. 2020, In Silico ADME/Tox Profiling of Natural Products: A Focus on BIOFACQUIM, ACS Omega, 5, 16076, 10.1021/acsomega.0c01581 · DOI · Paper page
  163. Negus, 2018, Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination, Curr. Top Behav. Neurosci., 39, 245, 10.1007/7854_2016_36 · DOI
  164. Maltarollo, 2015, Applying machine learning techniques for ADME-Tox prediction: A review, Expert Opin. Drug Met., 11, 259, 10.1517/17425255.2015.980814 · DOI · Paper page
  165. Wenzel, 2019, Predictive Multitask Deep Neural Network Models for ADME-Tox Properties: Learning from Large Data Sets, J. Chem. Inf. Model., 59, 1253, 10.1021/acs.jcim.8b00785 · DOI · Paper page
  166. Almazroo, 2017, Drug Metabolism in the Liver, Clin. Liver Dis., 21, 1, 10.1016/j.cld.2016.08.001 · DOI · Paper page
  167. Xu, 2021, Research on the Species Difference of the Hepatotoxicity of Medicine Based on Transcriptome, Front. Pharmacol., 12, 647084, 10.3389/fphar.2021.647084 · DOI
  168. Bjornsson, 2015, Drug-induced liver injury: An overview over the most critical compounds, Arch. Toxicol., 89, 327, 10.1007/s00204-015-1456-2 · DOI
  169. Walker, 2020, The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development, Arch. Toxicol., 94, 2559, 10.1007/s00204-020-02763-w · DOI
  170. Takebe, 2018, The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development, Clin. Transl. Sci., 11, 597, 10.1111/cts.12577 · DOI · Paper page
  171. Clinton, 2021, Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature, Drug Saf., 44, 1125, 10.1007/s40264-021-01109-4 · DOI
  172. Ai, 2018, Predicting Drug-Induced Liver Injury Using Ensemble Learning Methods and Molecular Fingerprints, Toxicol. Sci., 165, 100, 10.1093/toxsci/kfy121 · DOI
  173. Li, 2022, Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future, Front. Cardiovasc. Med., 9, 966261, 10.3389/fcvm.2022.966261 · DOI
  174. Food and Drug Administration (2005). International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Fed. Regist., 70, 61133–61134.
  175. Lamothe, 2016, The Human Ether-a-go-go-related Gene (hERG) Potassium Channel Represents an Unusual Target for Protease-mediated Damage, J. Biol. Chem., 291, 20387, 10.1074/jbc.M116.743138 · DOI
  176. Babcock, 2013, hERG channel function: Beyond long QT, Acta Pharmacol. Sin., 34, 329, 10.1038/aps.2013.6 · DOI
  177. Pettersson, 2005, Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death, Eur. Heart J., 26, 590, 10.1093/eurheartj/ehi092 · DOI · Paper page
  178. Thomas, 2006, The cardiac hERG/I-Kr potassium channel as pharmacological target: Structure, function, regulation, and clinical applications, Curr. Pharm. Des., 12, 2271, 10.2174/138161206777585102 · doi:10.2174/138161206777585102
  179. Stergiopoulos, 2021, Prediction of hERG inhibition of drug discovery compounds using biomimetic HPLC measurements, ADMET DMPK, 9, 191
  180. Honma, 2020, An assessment of mutagenicity of chemical substances by (quantitative) structure-activity relationship, Genes Environ., 42, 23, 10.1186/s41021-020-00163-1 · doi:10.1186/s41021-020-00163-1
  181. Zhang, 2017, CarcinoPred-EL: Novel models for predicting the carcinogenicity of chemicals using molecular fingerprints and ensemble learning methods, Sci. Rep., 7, 2118, 10.1038/s41598-017-02365-0 · DOI · Paper page
  182. Basu, A.K. (2018). DNA Damage, Mutagenesis and Cancer. Int. J. Mol. Sci., 19. · DOI · Paper page
  183. Drevon, 1981, Mutagenicity Assays of Estrogenic Hormones in Mammalian Cells, Mutat. Res., 89, 83, 10.1016/0165-1218(81)90134-8 · DOI
  184. Ferguson, 2010, Chronic inflammation and mutagenesis, Mutat. Res. Fund. Mol. Mech. Mutagenes., 690, 3, 10.1016/j.mrfmmm.2010.03.007 · DOI
  185. Barnes, 2018, Carcinogens and DNA damage, Biochem. Soc. T, 46, 1213, 10.1042/BST20180519 · DOI · Paper page
  186. Fradkin, 2022, A graph neural network approach for molecule carcinogenicity prediction, Bioinformatics, 38, i84, 10.1093/bioinformatics/btac266 · DOI
  187. Bartsch, 1983, Comparison between Carcinogenicity and Mutagenicity Based on Chemicals Evaluated in the IARC Monographs, Environ. Health Persp., 47, 305, 10.1289/ehp.8347305 · DOI
  188. Knuiman, 1987, Inter-Laboratory Variability in Ames Assay Results, Mutat. Res., 180, 171, 10.1016/0027-5107(87)90212-0 · doi:10.1016/0027-5107(87)90212-0
  189. Galloway, 2017, International Regulatory Requirements for Genotoxicity Testing for Pharmaceuticals Used in Human Medicine, and Their Impurities and Metabolites, Environ. Mol. Mutagen., 58, 296, 10.1002/em.22077 · doi:10.1002/em.22077
  190. Li, 2022, DeepCarc: Deep learning-powered carcinogenicity prediction using model-level representation, Front. Artif. Intell., 4, 757780, 10.3389/frai.2021.757780 · DOI
  191. Zaslayskiy, 2019, ToxicBlend: Virtual screening of toxic compound with ensemble predictors, Comput. Toxicol., 10, 81, 10.1016/j.comtox.2019.01.001 · DOI
  192. Sharma, 2023, Accurate clinical toxicity prediction using multi-task deep neural nets and contrastive molecular explanations, Sci. Rep., 13, 4908, 10.1038/s41598-023-31169-8 · DOI
  193. Gold, 2005, Supplement to the Carcinogenic Potency Database (CPDB): Results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997–1998, Toxicol. Sci., 85, 747, 10.1093/toxsci/kfi161 · DOI
  194. Veith, 2009, Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries, Nat. Biotechnol., 27, 1050, 10.1038/nbt.1581 · DOI · Paper page
  195. Yang, 2019, admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties, Bioinformatics, 35, 1067, 10.1093/bioinformatics/bty707 · DOI · Paper page
  196. Wei, 2022, Interpretable-ADMET: A web service for ADMET prediction and optimization based on deep neural representation, Bioinformatics, 38, 2863, 10.1093/bioinformatics/btac192 · DOI
  197. Zhang, 2022, HelixADMET: A robust and endpoint extensible ADMET system incorporating self-supervised knowledge transfer, Bioinformatics, 38, 3444, 10.1093/bioinformatics/btac342 · DOI
  198. Liu, 2021, Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure, Biol. Direct, 16, 6, 10.1186/s13062-020-00285-0 · DOI
  199. Lim, 2023, Supervised chemical graph mining improves drug-induced liver injury prediction, iScience, 26, 105677, 10.1016/j.isci.2022.105677 · DOI
  200. Kadioglu, 2021, Selection of safe artemisinin derivatives using a Mach. Learn.-based cardiotoxicity platform and in vitro and in vivo validation, Arch. Toxicol., 95, 2485, 10.1007/s00204-021-03058-4 · DOI

200 of 205 shown

Cited by

See all 176

Metadata

Authors
Han, R., Yoon, H., Kim, G., Lee, H., & Lee, Y.
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2023-09-06
Volume
16
Issue
9
Pages
1259
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4386483965
Cited by
176
References
31
FWCI
23.16
Type
journal article
Language
en
Open access
gold
Funders
  • National Research Foundation of Korea (2021M3E5E3080529, 2022R1C1C1007409)
  • Chung-Ang University Graduate Research Scholarship in 2023 (2021M3E5E3080529, 2022R1C1C1007409)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. https://app.cochat.ai/papers/10.3390/ph16091259
The paper
Han, R., Yoon, H., Kim, G., Lee, H., & Lee, Y. (2023). Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. Pharmaceuticals. https://doi.org/10.3390/ph16091259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.